CYDY (CytoDyn) Operating Margin %: 0.00% (As of Feb. 2026)


CYDY CytoDyn Inc CYDY
28 GF Score
Price $0.24
! 1 Warning Sign
View Full Analysis

What is CytoDyn Operating Margin %?

CytoDyn CYDY -2.38% 28 Operating Margin % is 0.00% as of Feb. 2026. GuruFocus rates CYDY with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, CytoDyn ranks worse than 105820% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. CytoDyn's Operating Income for the three months ended in Feb. 2026 was $-6.30 Mil. CytoDyn's Revenue for the three months ended in Feb. 2026 was $0.00 Mil. Therefore, CytoDyn's Operating Margin % for the quarter that ended in Feb. 2026 was 0.00%.

The historical rank and industry rank for CytoDyn's Operating Margin % or its related term are showing as below:


CYDY's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.89
* Ranked among companies with meaningful Operating Margin % only.

CytoDyn's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

CytoDyn's Operating Income for the three months ended in Feb. 2026 was $-6.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2026 was $-21.42 Mil.


CytoDyn  (OTCPK:CYDY) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


CytoDyn Operating Margin % Related Terms


CytoDyn Operating Margin % Historical Data

* Premium members only.

The historical data trend for CytoDyn's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Operating Margin % Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -54,663.16 0.00 0.00 0.00

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CYDY vs ZURA, XFOR, LYEL: Operating Margin % Comparison

For the Biotechnology subindustry, CytoDyn's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Operating Margin % distribution charts can be found below:

* The bar in red indicates where CytoDyn's Operating Margin % falls into.


CYDY
28GF Score
CytoDyn Inc CYDY
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

CytoDyn's Operating Margin % for the fiscal year that ended in May. 2025 is calculated as

Operating Margin %=Operating Income (A: May. 2025 ) / Revenue (A: May. 2025 )
=9.661 / 0
= %

CytoDyn's Operating Margin % for the quarter that ended in Feb. 2026 is calculated as

Operating Margin %=Operating Income (Q: Feb. 2026 ) / Revenue (Q: Feb. 2026 )
=-6.303 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
CytoDyn (CYDY) has a Operating Margin % of 0.00% as of Feb. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on CytoDyn and its competitors. According to the industry distribution chart, CytoDyn ranks #999999 out of 945 companies in the Biotechnology industry.
Is CytoDyn's Operating Margin % too high?
CytoDyn's current Operating Margin % is 0.00%. Based on the distribution chart, CytoDyn ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Operating Margin % compare to ZURA and XFOR?
According to the Biotechnology industry distribution chart, CytoDyn ranks #999999 out of 945 companies for Operating Margin %. This places CytoDyn in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on CytoDyn and its competitors. CytoDyn's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (CYDY) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For CytoDyn (CYDY), the current Operating Margin % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges 296:Germany
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for CYDY

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price